Smith & Nephew plc (NYSE:SNN) Q2 2020 Earnings Conference Call July 29, 2020 3:30 AM ET Company Participants Roland Diggelmann - CEO Ian Melling - Interim Chief Financial Officer Conference Call Participants Patrick Wood - Bank of America Merrill Lynch Kit Lee - Jefferies International Kyle Rose - Canaccord Genuity Christoph Gretler - Credit Suisse Julien Dormois - Exane BNP Paribas Michael Jungling - Morgan Stanley David Adlington - JPMorgan Chase Veronika Dubajova - Goldman Sachs International Tom Jones - ...

Smith Nephew Second Quarter and First Half 2020 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "wellplaced", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intende ...

Smith & Nephew plc (NYSE:SNN) Q4 2019 Earnings Conference Call February 20, 2020 4:00 AM ET | --- | |--------------------------------------------------------------| | | | Company Participants | | Roland Diggelmann - CEO Graham Baker - CFO | | Conference Call Participants | | David Adlington - JPMorgan Michael Jungling - Morgan Stanley | | | | Kyle Rose - Canaccord Veronika Dubajova - Goldman Sachs | | Tom Jones - Berenberg | | Kit Lee - Jefferies | | Ed Ridley - Redburn | | Chris Gretler - Credit Suisse | | ...

Smith Nephew Fourth Quarter and Full Year 2019 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "wellplaced", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended ...

Smith & Nephew PLC (NYSE:SNN) Q3 2019 Earnings Conference Call October 31, 2019 6:00 AM ET Company Participants | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Graham Baker – Chief Financial Officer Skip Kiil – President-Orthopaedics | | | Conference Call Participants | | | Patrick Wood – Bank of America | | | Kyle Rose – Canaccord Genuity Veronika Dubajova – Goldman Sachs ...

Q3 2019 Financial Performance - Smith+Nephew's Q3 revenue reached $1,246 million, reflecting a +4.0% underlying growth and +6.5% reported growth[6, 11] - Orthopaedics franchise revenue was $524 million, with an underlying growth of +3.4%[7, 15] - Sports Medicine & ENT franchise revenue amounted to $365 million, showing an underlying growth of +6.9%[8, 19] - Advanced Wound Management franchise revenue was $357 million, with an underlying growth of +2.1%[7, 22] Geographical Performance - US revenue reached $624 million, representing a growth of +2.7%[12, 13] - Other Established Markets generated $382 million in revenue, experiencing a decline of -0.3%[12, 13] - Emerging Markets revenue was $240 million, demonstrating a growth of +16.0%[12, 14] Orthopaedics Sub-Franchise Performance - Knees sub-franchise showed a global growth of +4.6%, with US at +1.7% and OUS at +8.6%[15] - Hips sub-franchise grew globally by +2.6%, with US at +2.2% and OUS at +3.1%[15] - Trauma sub-franchise experienced a growth of +2.2%[15] Sports Medicine & ENT Sub-Franchise Performance - Sports Medicine Joint Repair (SMJR) grew by +12.2%[19] - Arthroscopic Enabling Technologies (AET) grew by +0.8%[19] - ENT grew by +5.3%[19] Advanced Wound Management Sub-Franchise Performance - Advanced Wound Care (AWC) declined by -1.8%[22] - Advanced Wound Bioactives (AWB) grew by +2.1%[22] - Advanced Wound Devices (AWD) grew significantly by +15.4%[22] 2019 Guidance - The company projects sales growth with an underlying rate of 3.5% to 4.5% and a reported rate of 3.9% to 4.9%[48] - The trading profit margin is expected to be around 22.8%[48]

Smith & Nephew PLC (NYSE:SNN) Q2 2019 Earnings Conference Call July 31, 2019 3:30 AM ET Company Participants Namal Nawana - CEO Simon Fraser - President, Advanced Wound Management Graham Baker - CFO Conference Call Participants Patrick Wood - Bank of America Merrill Lynch David Adlington - JPMorgan Chase & Co. Kyle Rose - Canaccord Genuity Corp. Nyeok Lee - Jefferies Michael Jungling - Morgan Stanley Veronika Dubajova - Goldman Sachs Group Thomas Jones - Berenberg Julien Dormois - Exane BNP Paribas Namal Na ...

SN © Smith+Nephew 2019 Second Quarter and First Half 2019 Results Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "wellplaced", "believe", "estimate", "expect", "target", "consider" and similar expressions are general ...

% smith&nephew Unlimited First Quarter 2019 Trading Report TLTTe Forward looking statements and non-IFRS measures This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are general ...

Financial Data and Key Metrics Changes - Smith & Nephew reported a 4.4% underlying growth rate in Q1 2019, with all three franchises accelerating from 2018 performance [5] - The U.S. market, which constitutes about half of the business, grew by 4%, while emerging markets saw over 15% growth, particularly driven by China, which exceeded 20% growth in the quarter [5] - The company expects reported sales growth for 2019 to be between 2.9% and 3.9%, with trading profit margin guidance between 22.8% and 23.2% [32][33] Business Line Data and Key Metrics Changes - Orthopaedics grew by 3.9%, with knees growing by 4.1% and hips by 2.4%. Trauma grew by 4.8%, driven by an 8% growth in plates and screws [6][7] - Sports Medicine & ENT was the highest growth franchise at 5.3%, with joint repair business growing by 11% [9] - Advanced Wound Management grew by 4.1%, with Advanced Wound Devices showing significant growth of 16.4% [11] Market Data and Key Metrics Changes - Emerging markets, particularly China and India, are expected to drive sales growth in the Asia Pacific region for the remainder of the year [5] - Other Established Markets showed slight negative growth, although Europe returned to positive growth after a decline in the previous year [5] Company Strategy and Development Direction - The company is focusing on M&A strategy, having closed several acquisitions including Ceterix, Osiris, and Leaf, which are expected to enhance growth in high-potential segments [12][13][14] - Smith & Nephew is advancing in digital surgery and robotics, with plans to launch next-generation robotic platforms and software in the second half of 2019 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year sales growth in the upper half of the guidance range due to a strong start in Q1 [32] - The company is optimistic about its positioning in the market, citing favorable demographics and demand for better clinical outcomes [28] Other Important Information - The company announced the appointment of Myra Eskes as the new President for Asia Pacific, expected to enhance leadership in a strong-performing region [17] - Management emphasized the importance of a solutions approach in sales, particularly in the Sports Medicine segment [20] Q&A Session Summary Question: How have changes in sales and marketing impacted performance? - Management indicated that the focus on sales and marketing was to maximize existing assets and improve customer care, which was identified as a key area for improvement [37] Question: How does the company compare to competitors post-changes? - Management believes the portfolio is competitive and well-positioned within the market [38] Question: What is the outlook for the Sports Medicine business in China? - Management expects to grow at or above market rates, supported by unique assets and geographic positions [45] Question: What does financial discipline mean in the context of M&A? - Management clarified that financial discipline involves assessing multiple financial lenses and ensuring strong returns on investments from acquisitions [47] Question: What is the company's appetite for smaller versus larger acquisitions? - Management is open to both smaller and larger acquisitions, emphasizing a proactive approach to identifying opportunities [53] Question: What is the outlook for the hip and knee market? - Management noted that while there may be quarterly variances, the overall market remains solid with good growth prospects [61] Question: What is the competitive situation in Europe for Advanced Wound Care? - Management acknowledged ongoing price pressure in Europe but highlighted positive performance in the U.S. market [80]